GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dermira Inc (NAS:DERM) » Definitions » EPS without NRI

Dermira (Dermira) EPS without NRI : $-4.58 (TTM As of Sep. 2019)


View and export this data going back to 2014. Start your Free Trial

What is Dermira EPS without NRI?

Dermira's earnings per share without non-recurring items for the three months ended in Sep. 2019 was $-1.06. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2019 was $-4.58.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Dermira's EPS without NRI or its related term are showing as below:

DERM's 3-Year EPS without NRI Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 4.9
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Dermira's EPS (Diluted) for the three months ended in Sep. 2019 was $-1.06. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2019 was $-4.58.

Dermira's EPS (Basic) for the three months ended in Sep. 2019 was $-1.06. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2019 was $-4.58.


Dermira EPS without NRI Historical Data

The historical data trend for Dermira's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dermira EPS without NRI Chart

Dermira Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
EPS without NRI
Get a 7-Day Free Trial -4.96 -2.93 -2.70 -7.48 -5.27

Dermira Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.58 -1.70 -1.49 -0.33 -1.06

Competitive Comparison of Dermira's EPS without NRI

For the Biotechnology subindustry, Dermira's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dermira's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dermira's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Dermira's PE Ratio without NRI falls into.



Dermira EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dermira  (NAS:DERM) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Dermira EPS without NRI Related Terms

Thank you for viewing the detailed overview of Dermira's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Dermira (Dermira) Business Description

Traded in Other Exchanges
N/A
Address
275 Middlefield Road, Suite 150, Menlo Park, CA, USA, 94025
Dermira Inc is a biopharmaceutical company focuses on the development and commercialization of medical dermatology products to dermatologists and their patients primarily in the United States.The company's late-stage product candidates include Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor to treat various inflammatory diseases, as well as to treat patients with moderate-to-severe chronic plaque psoriasis; Glycopyrronium tosylate, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and Olumacostat glasaretil, a small-molecule sebum inhibitor, which is in Phase III clinical trial to treat acne vulgaris or acne.
Executives
Halley E Gilbert director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
William R Ringo director
Fred B Craves director 750 BATTERY ST, STE 600, SAN FRANCISCO CA 94111
David E Cohen director 3160 PORTER DRIVE, PALO ALTO CA 94304
Thomas G Wiggans director, officer: CEO & Chairman of the Board
Jason Raleigh Nunn director 1119 ST. PAUL STREET, BALTIMORE MD 21202
Andrew Guggenhime officer: CFO C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Lori Lyons-williams officer: Chief Commercial Officer C/O DERMIRA, INC., 275 MIDDLEFIELD ROAD, SUITE 150, MENLO PARK CA 94025
Kathleen Sebelius director C/O DERMIRA, INC., 275 MIDDLEFIELD ROAD, SUITE 150, MENLO PARK CA 94025
Eugene A Bauer director, officer: Chief Medical Officer C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
Lilly Eli & Co 10 percent owner LILLY CORPORATE CENTER, DROP CODE 1094, INDIANAPOLIS IN 46285
Mark Mcdade director C/O PROTINE DESIGN LAB, 7442 NORTH MARCER WAY, MERCER ISLAND WA 98040
Matthew K Fust director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Canaan Partners Viii Llc director 285 RIVERSIDE AVE, STE 250, WESTPORT CT 06880
Canaan Viii Lp director 2765 SAND HILL RD, MENLO PARK CA 94025

Dermira (Dermira) Headlines

From GuruFocus

This Insider Just Sold Shares of Journey Medical Corp

By GuruFocus Research GuruFocus Editor 05-20-2023